Outcomes of basiliximab <i>vs</i> alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study.

Finally, although the incidence of acute rejection was numerically higher among recipients of alemtuzumab, the difference did not reach statistical significance after adjustment for pre-emptive transplantation, PRA, and propensity scores (OR = 2.10; 95%CI: 0.88-4.93; P = 0.110).

also in 111,027 other papers